Business
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
New data from in vitro, in vivo, and IND enabling studies supports LP-284’s development for MCL, an aggressive form of B-cell non-Hodgkin's lymphoma (NHL)
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nNew data from in vitro, in vivo, and IND enabling studies supports LP-284’s development for MCL, an aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with immediate patient needs.\n\n\nLantern is anticipating filing the IND with the FDA in early 2023 and initiating a first-in-human Phase 1 trial for LP-284 in NHLs, including MCL and double hit lymphoma (DHL), by mid 2023.\n\n\nIn the US and Europe, MCL and DHL are diagnosed in approximately 9,000 patients each year and have an estimated annual market potential of $1.2 billion USD.\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it presented new positive preclinical data for its drug candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology Annual meeting.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005355/en/Figure 1. In mice implanted with MCL CDX tumors that had been treated and then grown resistant to Bortezomib or Ibrutinib, subsequent LP-284 treatment of 4 mg/kg (i.v.) resulted in near complete tumor regression in the SOC resistant MCL CDX tumors (** p \nThe ASH poster highlights new results for LP-284 from preclinical studies for MCL and initial results from investigational new drug (IND) enabling studies. LP-284 treatment was demonstrated to have significantly greater tumor growth inhibition (TGI) in mice implanted with MCL cell derived xenograft (CDX) tumors, when compared to treatment with the standard-of-care (SOC) agents Ibrutinib or Bortezomib (see Table 1).\n\nTable 1.\n\n\n\nAgent (Dose; Administration)\n\n\n\nLP-284\n\n\n(4 mg/kg; i.v.)\n\n\n\nLP-284\n\n\n(2 mg/kg; i.v.)\n\n\n\nBortezomib\n\n\n(1 mg/kg; i.p.)\n\n\n\nIbrutinib\n\n\n(50 mg/kg; p.o.)\n\n\n\n\n\nTGI (%)\n\n\n\n113%\n\n\n\n63%\n\n\n\n22%\n\n\n\n8%\n\n\n\n\n\nTable Legend: Tumor growth inhibition (TGI); Intravenous (i.v.); Intraperitoneal (i.p.); Oral (p.o.)\n\n\n\n\nAdditionally, in mouse MCL CDX tumors that had been treated and then grown resistant to either Ibrutinib or Bortezomib, subsequent LP-284 treatment of 4 mg/kg (i.v.) res...